Search - tctmd.com

Displaying 1 - 20 of 48

Sort: Relevancy | Date

News Conference News

Watchman, Amulet LAA Closure Devices Carry Low Complication Rates

Todd Neale

November 04, 2016

News Industry News

SentreHEART Announces Closing of $35M Funding Round for aMAZE Trial

October 03, 2016

News Daily News

研究肯定了 Watchman 左心耳封堵器减少卒中的成本效益

L.A. McKeown

December 14, 2015

News Daily News

Un Estudio Confirma la Rentabilidad del Dispositivo Watchman para el Cierre del AAI en el Descenso de ACV

L.A. McKeown

December 14, 2015

News Daily News

Study Affirms Cost-Effectiveness of Watchman LAA Closure Device for Stroke Reduction

L.A. McKeown

December 14, 2015

Presentation

Time to Cost-Effectiveness After Stroke Reduction Strategies in A-fib: Warfarin vs Novel Oral Anticoagulants (NOACs) vs Left Atrial Appendage (LAA) Closure

Presenter: Vivek Y. Reddy

December 13, 2015

News Industry News

Boston Scientific Receives CE Mark For Next Generation WATCHMAN FLX™ Left Atrial Appendage Closure Device

November 19, 2015

News Daily News

Good News, Bad News Week for Watchman LAA Occluder

Shelley Wood

November 12, 2015

News Daily News

PROTECT AF at 4 Years: LAA Closure Maintains Efficacy Over Warfarin

Caitlin E. Cox

November 19, 2014

Presentation

Percutaneous LAA Closure vs Warfarin for A-fib:A Randomized Clinical Trial

Presenter: Vivek Y. Reddy

November 19, 2014

Presentation TCT 2014

Cost-effectiveness Analysis Of Left Atrial Appendage Occlusion Device Compared With 7 Oral Anticoagulants For Stroke Prevention In Atrial Fibrillation

Presenter: Vivian Lee

September 16, 2014

Presentation TCT 2014

TCT 170: Cost-effectiveness Analysis of a Left Atrial Appendage Occlusion Device Compared with 7 Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation

Presenter: Saibal Kar, Bushra S Rana, Jai-Wun Park, Vivian Lee

September 15, 2014

Presentation TCT 2014

AF Ablation: Stand-Alone and in Conjunction with LAA Closure

Presenter: Shephal Doshi, Gregg W. Stone, Steven R. Bailey, Vivek Y. Reddy

September 15, 2014

Presentation TCT 2014

Watchman I: First Report of the 5-Year PROTECT-AF and Extended PREVAIL Results

Presenter: Shephal Doshi, Gregg W. Stone, Steven R. Bailey, Vivek Y. Reddy

September 15, 2014

News Conference News TCT 2014

LAA Closure Edges Out Medical Therapy for Cost-effectiveness in AF

September 14, 2014

Presentation TCT 2014

Watchman Nightmare Case and Teaching Moment #2: Improper Device Sizing with Embolization

Presenter: Josep Rodés-Cabau, Carlos E. Ruiz, Vivek Y. Reddy

September 13, 2014

Presentation LAA 2014

Watchman: Registry Data from the “Real-World”

Presenter: Vivek Y. Reddy

July 19, 2014

Presentation LAA 2014

Watchman: Non-Randomized Trial Data in Anticoagulant Ineligible Patients ASAP and more

Presenter: Vivek Y. Reddy

July 19, 2014

Presentation LAA 2014

Case 2: Watchman Implantation

Presenter: Vivek Y. Reddy

July 19, 2014

Presentation LAA 2014

Novel LAA Closure Technologies on the Horizon

Presenter: Vivek Y. Reddy

July 17, 2014

Advertisement

Watchman, Amulet LAA Closure Devices Carry Low Complication Rates

SentreHEART Announces Closing of $35M Funding Round for aMAZE Trial

研究肯定了 Watchman 左心耳封堵器减少卒中的成本效益

Un Estudio Confirma la Rentabilidad del Dispositivo Watchman para el Cierre del AAI en el Descenso de ACV

Study Affirms Cost-Effectiveness of Watchman LAA Closure Device for Stroke Reduction

Time to Cost-Effectiveness After Stroke Reduction Strategies in A-fib: Warfarin vs Novel Oral Anticoagulants (NOACs) vs Left Atrial Appendage (LAA) Closure

Boston Scientific Receives CE Mark For Next Generation WATCHMAN FLX™ Left Atrial Appendage Closure Device

Good News, Bad News Week for Watchman LAA Occluder

PROTECT AF at 4 Years: LAA Closure Maintains Efficacy Over Warfarin

Percutaneous LAA Closure vs Warfarin for A-fib:A Randomized Clinical Trial

Cost-effectiveness Analysis Of Left Atrial Appendage Occlusion Device Compared With 7 Oral Anticoagulants For Stroke Prevention In Atrial Fibrillation

TCT 170: Cost-effectiveness Analysis of a Left Atrial Appendage Occlusion Device Compared with 7 Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation

AF Ablation: Stand-Alone and in Conjunction with LAA Closure

Watchman I: First Report of the 5-Year PROTECT-AF and Extended PREVAIL Results

LAA Closure Edges Out Medical Therapy for Cost-effectiveness in AF

Watchman Nightmare Case and Teaching Moment #2: Improper Device Sizing with Embolization

Watchman: Registry Data from the “Real-World”

Watchman: Non-Randomized Trial Data in Anticoagulant Ineligible Patients ASAP and more

Case 2: Watchman Implantation

Novel LAA Closure Technologies on the Horizon

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content